• Recce receives Advanced Overseas Finding for up to A$85m R&D expenditure
• Extends 43.5% R&D Tax Incentive rebate to Recce's overseas activities
• Covers domestic and overseas R&D, including Phase 3 Diabetic Foot Infection trial

Recce Pharmaceuticals Ltd (ASX:RCE) has received an Advanced Overseas Finding from the Australian Department of Industry, Science and Resources for up to A$85 million in R&D expenditure. This finding confirms that Recce's R&D activities undertaken outside Australia are eligible and qualify for the 43.5% R&D Tax Incentive, extending the rebate beyond domestic activities for a three-year period. The finding covers Recce's domestic and overseas R&D programs, including its Phase 3 Diabetic Foot Infection (DFI) clinical trial in Indonesia and further overseas R&D within its infectious disease portfolio. This represents one of the largest Advanced Overseas Findings in Australian history, supporting Recce's global anti-infective programs. The binding decision from the Australian Government recognizes the importance of Recce's work in combating antibiotic resistance, with the company's synthetic anti-infective pipeline including three patented, broad-spectrum treatments for serious bacterial and viral infections.

The Advanced Overseas Finding provides confirmation that Recce's R&D activities undertaken outside Australia are eligible and qualify for the 43.5% R&D Tax Incentive, extending the rebate beyond domestic activities for a three-year period.